Aufrufe
vor 5 Monaten

Life Sciences Report 2017 / 2018

  • Text
  • Technology
  • Medicine
  • Pharma
  • Berlin
  • Innovative
  • Clinical
  • Sciences
  • Solutions
  • Pharmaceutical
  • Biotech
  • Diagnostics

22 Life

22 Life Sciences Report 2015 – Hot Topics COMMITTED TO PATIENTS HOPE IS WHAT SANOFI BRINGS EACH DAY, OVERCOMING NEW CHALLENGES TO PROTECT LIFE FOR SEVEN BILLION PEOPLE. One of the world’s leading health care companies, Sanofi researches, develops, manufactures and markets innovative therapeutic solutions that prevent disease, heal and improve quality of life for patients and their families. www.sanofi.com © Pierre-Olivier/Capa Pictures - 1701_XXK_H

Life Sciences Report – In vitro Diagnostics 23 In vitro Diagnostics According to the latest statistics from the German Diagnostics Industry Association (VDGH*), the German diagnostics market totaled approx. 2.2 billion € in 2016, making it the largest in Europe. Berlin- Brandenburg has extraordinary expertise in the areas of in vitro diagnostics and bioanalytics. Twenty research institutions are working on identifying new biomarkers and new platform technologies for diagnostic tools. Research in this area is mainly focused on point of care testing, high throughput screening, biosensors, next generation sequencing, glycan-based array platforms, and automation. * Source: https://www.vdgh.de/marktdaten/deutschland2/diagnostica-markt Clear and precise diagnostics are indispensable for targeted therapies. Biomarker development is currently seeing rapid progress in diagnostics, progress monitoring, population screenings, and disease prevention. Today, 70 percent of the decision on how to treat an illness depends on the results of such tests. Due to the increasing use of high-throughput technologies in areas such as genomics, proteomics, and metabolomics, more and more biomarkers are available for use in new in vitro diagnostics techniques. In addition, stratification of patients or patient groups based on biomarkers opens up new and more appropriate treatment options. Illnesses originally viewed as “one” disease can be divided into subtypes through precise analysis of associated biomarkers – with highly relevant consequences for treatment. The development of associated “companion diagnostics” is currently taking off, as is clear when we consider current licensing figures from the FDA. Cancers such as colon cancer, lung cancer, and ovarian tumors are just some examples. As knowledge grows in the field of biomarkers and associated illnesses, applications of these companion diagnostics will also be expanded to other indications. More targeted treatments based on more precise diagnostics mean IvD and companion diagnostics have the potential to minimize illness-related costs and improve patients’ lives. The entire value chain The development of innovative diagnostics covers the four areas of basic research, technology development, clinical validation of biomarkers in clinical trials, and industrial development and applications. The capital region is well positioned to handle these areas, providing the entire value chain from basic scientific research to production and marketing. The many research facilities, hospitals, and biomedical and pharmaceutical companies in the region provide advantages for everyone involved in the value chain. Within the region, networks support developments in the diagnostics area and are key actors in the biotechnology and pharmaceutical fields: • GlycoNet BB is a platform supporting collaboration between partners in the glycoscience area. It promotes the development of innovative products in this field. • DiagnostikNet BB supports cooperation and developments in the area of diagnostics. 10 years of excellence in in vitro diagnostics The network “Diagnostik Berlin-Brandenburg e.V.”, which was founded 10 years ago, it’s a true success story: The association has brought together innovative companies, renowned international research institutions, and laboratories and expert partners from Berlin-Brandenburg and six other federal states to jointly develop, manufacture, and sell in vitro diagnostic products. The network combines the diverse areas of expertise of its over 65 members, covering the entire value chain for in vitro diagnostics. In addition to human medicine diagnostics, other fields of application include veterinary diagnostics, mobile health, food, and agriculture & environment. Its customers include laboratories, pharmaceutical manufacturers, and clinics. The network’s subsidiary, Diagnostik BB GmbH, is a professional seminar and workshop provider and supplies various consulting and project management services specialized on the in vitro diagnostics area. www.DiagnostikNet-BB.de

Publications in English

Publikationen auf deutsch

Clusterreport Verkehr, Mobilität und Logistik
Schienenverkehrstechnik
Verkehrstelematik
Logistik
Automotive in der Hauptstadtregion Berlin-Brandenburg
Aerospace Industrie
Biotech- und Pharmaindustrie
Forschung für die Gesundheit
Gesundheitsversorgung und Prävention
Potenzialstudie Medizintourismus Berlin-Brandenburg_2015
Clusterbroschuere Gesundheitswirtschaft
Prävention und Gesundheitsförderung
Rehabilitation in Berlin und Brandenburg
Games Industrie in der Hauptstadtregion Berlin-Brandenburg
Digitale Wirtschaft in Berlin
Fernsehen in der Hauptstadtregion Berlin-Brandenburg
Fashion in Berlin
Best Practice Wireless in der Hauptstadtregion Berlin-Brandenburg
Medien und Kreativwirtschaft in Berlin-Brandenburg
Turbomaschinen und Kraftwerkstechnik
Energienetze und -speicher in der Hauptstadtregion Berlin-Brandenburg
Kreislaufwirtschaft in Berlin
Wasserwirtschaft in Berlin
Energietechnik in der Hauptstadtregion Berlin-Brandenburg
Service Packages für Unternehmen in Berlin
Unternehmensservice in den Berliner Bezirken
Berlin Partner: Unser Service fuer Sie